Toward global prevention of sexually transmitted infections (STIs): The need for STI vaccines

Vaccine

Volumn 32, Issue 14, 2014, Pages 1527-1535

  Gottlieb, Sami L ^a   Low, Nicola ^b   Newman, Lori M ^a   Bolan, Gail ^c   Kamb, Mary ^c   Broutet, Nathalie ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Prevention and control; Sexually transmitted diseases; Vaccines

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIAL VACCINE; CEPHALOSPORIN DERIVATIVE; NITROIMIDAZOLE DERIVATIVE; PROTOZOAL VACCINE; VIRUS VACCINE;

AFRICA SOUTH OF THE SAHARA; ANTIBIOTIC RESISTANCE; ANUS CANCER; ARTICLE; ASYMPTOMATIC INFECTION; BEHAVIOR CHANGE; BLINDNESS; BREAST CANCER; CASE MANAGEMENT; CHLAMYDIA; CHLAMYDIASIS; CONDOM USE; CONGENITAL SYPHILIS; CONTROL STRATEGY; DEATH; ECTOPIC PREGNANCY; FETUS DEATH; GONORRHEA; HEALTH CARE COST; HEPATITIS B; HEPATITIS B VIRUS; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; INCIDENCE; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RATE; INFECTION RISK; INFERTILITY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LOW BIRTH WEIGHT; LOWEST INCOME GROUP; MATERNAL WELFARE; NEWBORN DEATH; NEWBORN OPHTHALMIA; OROPHARYNX CANCER; PAPANICOLAOU TEST; PARTNER VIOLENCE; PELVIC INFLAMMATORY DISEASE; PELVIS PAIN SYNDROME; PENIS CANCER; PNEUMONIA; POPULATION; PREGNANCY COMPLICATION; PREMATURE LABOR; PREMATURITY; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; PUBLIC HEALTH PROBLEM; QUALITY OF LIFE; RISK REDUCTION; SCREENING; SEROPREVALENCE; SEXUAL PRACTICE; STILLBIRTH; SYPHILIS; TRADITIONAL HEALER; TREATMENT FAILURE; TRICHOMONIASIS; UNITED STATES; UNSAFE SEX; UPPER GENITAL TRACT DISEASE; URETHRITIS; UROGENITAL TRACT DISEASE; UTERINE CERVICITIS; UTERINE CERVIX CANCER; VACCINATION; VAGINA CANCER; VAGINA DISCHARGE; VERRUCA VULGARIS; VIRUS LOAD; VIRUS TRANSMISSION; WART VIRUS;

PREVENTION AND CONTROL; SEXUALLY TRANSMITTED DISEASES; VACCINES;

COST OF ILLNESS; HUMANS; PUBLIC HEALTH; SEXUALLY TRANSMITTED DISEASES; VACCINATION; VACCINES; WORLD HEALTH;

EID: 84896723343     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.07.087     Document Type: Article

References (108)

1. World Health Organization Reproductive Health Strategy to Accelerate Progress Towards the Attainment of International Development Goals and Targets 2004, World Health Organization, Geneva, http://www.who.int/reproductivehealth/publications/general/RHR_04_8/en/.
2. UN Millennium Project Investing in Development: A Practical Plan to Achieve the Millennium Development Goals 2005, United Nations Development Programme, New York, http://www.who.int/hdp/publications/4b.pdf.
3. World Health Organization Hepatitis B vaccines: WHO position paper. Wkly Epidemiol Rec 2009, 84(40):405-420.
4. World Health Organization Prevention and Control of Viral Hepatitis Infection: Framework for Global Action 2012, World Health Organization, Geneva, http://www.who.int/csr/disease/hepatitis/GHP_framework.pdf.
5. World Health Organization Hepatitis B: Immunization surveillance, assessment, and monitoring 2013, http://www.who.int/immunization_monitoring/diseases/hepatitis/en/.
6. Schiller J.T., Castellsague X., Garland S.M. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012, 30(Suppl. 5):F123-F138.
7. Baandrup L., Blomberg M., Dehlendorff C., Sand C., Andersen K.K., Kjaer S.K. Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis 2013, 40(2):130-135.
8. Read T.R., Hocking J.S., Chen M.Y., Donovan B., Bradshaw C.S., Fairley C.K. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011, 87(7):544-547.
9. World Health Organization Global incidence and prevalence of selected curable sexually transmitted infections - 2008 2012, World Health Organization, Geneva, http://www.who.int/reproductivehealth/publications/rtis/stisestimates/en/index.html.
10. World Health Organization Prevalence and incidence of selected sexually transmitted infections, Chlamydia trachomatis, Neisseria gonorrhoeae, syphilis and Trichomonas vaginalis. Methods and results used by WHO to generate 2005 estimates 2011, World Health Organization, Geneva, http://www.who.int/reproductivehealth/publications/rtis/9789241502450/en/index.html.
11. de Sanjose S., Diaz M., Castellsague X., et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007, 7(7):453-459.
12. Dunne E.F., Nielson C.M., Stone K.M., Markowitz L.E., Giuliano A.R. Prevalence of HPV infection among men: a systematic review of the literature. J Infect Dis 2006, 194(8):1044-1057.
13. Smith J.S., Gilbert P.A., Melendy A., Rana R.K., Pimenta J.M. Age-specific prevalence of human papillomavirus infection in males: a global review. J Adolesc Health 2011, 48(6):540-552.
14. Looker K.J., Garnett G.P., Schmid G.P. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Organ 2008, 86(10):805-812. A.
15. Satterwhite C.L., Torrone E., Meites E., et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis 2013, 40(3):187-193.
16. Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years--United States, 2005-2008. MMWR Morb Mortal Wkly Rep 2010, 59(15):456-459. Centers for Disease Control and Prevention.
17. Watson-Jones D., Weiss H.A., Rusizoka M., et al. Risk factors for herpes simplex virus type 2 and HIV among women at high risk in northwestern Tanzania: preparing for an HSV-2 intervention trial. J Acquir Immune Defic Syndr 2007, 46(5):631-642.
18. Chico R.M., Mayaud P., Ariti C., Mabey D., Ronsmans C., Chandramohan D. Prevalence of malaria and sexually transmitted and reproductive tract infections in pregnancy in sub-Saharan Africa: a systematic review. JAMA 2012, 307(19):2079-2086.
19. World Health Organization Regional Office of the Western Pacific. HIV and sexually transmitted infections in the Western Pacific region, 2000-2010. 2012, World Health Organization Regional Office of the Western Pacific, Manila, http://www.wpro.who.int/publications/2012/document_hiv_and_sti_2000-2010.pdf.
20. Lin C.C., Gao X., Chen X.S., Chen Q., Cohen M.S. China's syphilis epidemic: a systematic review of seroprevalence studies. Sex Transm Dis 2006, 33(12):726-736.
21. Woodhall S., Ramsey T., Cai C., et al. Estimation of the impact of genital warts on health-related quality of life. Sex Transm Infect 2008, 84(3):161-166.
22. Dinh T.H., Sternberg M., Dunne E.F., Markowitz L.E. Genital warts among 18- to 59-year-olds in the United States, national health and nutrition examination survey, 1999-2004. Sex Transm Dis 2008, 35(4):357-360.
23. Kjaer S.K., Tran T.N., Sparen P., et al. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. J Infect Dis 2007, 196(10):1447-1454.
24. Aumakhan B., Gaydos C.A., Quinn T.C., et al. Clinical reactivations of herpes simplex virus type 2 infection and human immunodeficiency virus disease progression markers. PLoS One 2010, 5(4):e9973.
25. Denny L.A., Franceschi S., de S.S., Heard I., Moscicki A.B., Palefsky J. Human papillomavirus, human immunodeficiency virus and immunosuppression. Vaccine 2012, 30(Suppl. 5):F168-F174.
26. Johnson H.L., Ghanem K.G., Zenilman J.M., Erbelding E.J. Sexually transmitted infections and adverse pregnancy outcomes among women attending inner city public sexually transmitted diseases clinics. Sex Transm Dis 2011, 38(3):167-171.
27. Marchant T., Willey B., Katz J., et al. Neonatal mortality risk associated with preterm birth in East Africa, adjusted by weight for gestational age: individual participant level meta-analysis. PLoS Med 2012, 9(8):e1001292.
28. Newman L., Kamb M., Hawkes S., et al. Global estimates of syphilis in pregnancy and associated adverse outcomes: analysis of multinational antenatal surveillance data. PLoS Med 2013, 10(2):e1001396.
29. Schaller U.C., Klauss V. Is Crede's prophylaxis for ophthalmia neonatorum still valid?. Bull World Health Organ 2001, 79(3):262-263.
30. Schachter J., Grossman M., Sweet R.L., Holt J., Jordan C., Bishop E. Prospective study of perinatal transmission of Chlamydia trachomatis. JAMA 1986, 255(24):3374-3377.
31. Brown Z.A., Wald A., Morrow R.A., Selke S., Zeh J., Corey L. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA 2003, 289(2):203-209.
32. Dinh T.H., Dunne E.F., Markowitz L.E., Weinstock H., Berman S. Assessing neonatal herpes reporting in the United States, 2000-2005. Sex Transm Dis 2008, 35(1):19-21.
33. Hyams K.C. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis 1995, 20(4):992-1000.
34. Bosch F.X., de S.S. The epidemiology of human papillomavirus infection and cervical cancer. Dis Markers 2007, 23(4):213-227.
35. GLOBOCAN. International Agency for Research on Cancer. Cervical cancer incidence and mortality worldwide 2008, http://globocan.iarc.fr/factsheets/cancers/cervix.asp.
36. Goldstein S.T., Zhou F., Hadler S.C., Bell B.P., Mast E.E., Margolis H.S. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005, 34(6):1329-1339.
37. Haggerty C.L., Gottlieb S.L., Taylor B.D., Low N., Xu F., Ness R.B. Risk of sequelae after Chlamydia trachomatis genital infection in women. J Infect Dis 2010, 201(Suppl. 2):S134-S155.
38. Oakeshott P., Kerry S., Aghaizu A., et al. Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial. BMJ 2010, 340:c1642.
39. Westrom L., Joesoef R., Reynolds G., Hagdu A., Thompson S.E. Pelvic inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sex Transm Dis 1992, 19(4):185-192.
40. Hillis S.D., Joesoef R., Marchbanks P.A., Wasserheit J.N., Cates W., Westrom L. Delayed care of pelvic inflammatory disease as a risk factor for impaired fertility. Am J Obstet Gynecol 1993, 168(5):1503-1509.
41. Mascarhenas M.N., Flaxman S.R., Boerma T., Vanderpoel S., Stevens G.A. National, regional, and global trends in infertility prevalence since 1990: a systematic analysis of 277 health surveys. PLoS Med 2012, 9(12):e1001356.
42. Rutstein S.O., Shah I.H. Infecundity, infertility, and childlessness in developing countries. DHS Comparative Reports No. 9 2004, ORC Macro and the World Health Organization, Calverton, Maryland, USA.
43. Feinberg E.C., Larsen F.W., Catherino W.H., Zhang J., Armstrong A.Y. Comparison of assisted reproductive technology utilization and outcomes between Caucasian and African American patients in an equal-access-to-care setting. Fertil Steril 2006, 85(4):888-894.
44. Macaluso M., Wright-Schnapp T.J., Chandra A., et al. A public health focus on infertility prevention, detection, and management. Fertil Steril 2010, 93(1):16-20.
45. Cates W., Farley T.M., Rowe P.J. Worldwide patterns of infertility: is Africa different. Lancet 1985, 2(8455):596-598.
46. Freeman E.E., Weiss H.A., Glynn J.R., Cross P.L., Whitworth J.A., Hayes R.J. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006, 20(1):73-83.
47. Celum C., Wald A., Lingappa J.R., et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010, 362(5):427-439.
48. Gray R.H., Wawer M.J., Brookmeyer R., et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001, 357(9263):1149-1153.
49. Hayes R., Watson-Jones D., Celum C., van de Wijgert J., Wasserheit J. Treatment of sexually transmitted infections for HIV prevention: end of the road or new beginning. AIDS 2010, 24(Suppl 4):S15-S26.
50. Sexton J., Garnett G., Rottingen J.A. Metaanalysis and metaregression in interpreting study variability in the impact of sexually transmitted diseases on susceptibility to HIV infection. Sex Transm Dis 2005, 32(6):351-357.
51. Cohen M.S., Hoffman I.F., Royce R.A., et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. Lancet 1997, 349(9069):1868-1873.
52. Johnson L.F., Lewis D.A. The effect of genital tract infections on HIV-1 shedding in the genital tract: a systematic review and meta-analysis. Sex Transm Dis 2008, 35(11):946-959.
53. Houlihan C.F., Larke N.L., Watson-Jones D., et al. Human papillomavirus infection and increased risk of HIV acquisition. A systematic review and meta-analysis. AIDS 2012, 26(17):2211-2222.
54. Fortenberry J.D., McFarlane M., Bleakley A., et al. Relationships of stigma and shame to gonorrhea and HIV screening. Am J Public Health 2002, 92(3):378-381.
55. Gottlieb S.L., Stoner B.P., Zaidi A.A., et al. A prospective study of the psychosocial impact of a positive Chlamydia trachomatis laboratory test. Sex Transm Dis 2011, 38(11):1004-1011.
56. Mortensen G.L., Larsen H.K. The quality of life of patients with genital warts: a qualitative study. BMC Public Health 2010, 10:113.
57. Decker M.R., Miller E., McCauley H.L., et al. Intimate partner violence and partner notification of sexually transmitted infections among adolescent and young adult family planning clinic patients. Int J STD AIDS 2011, 22(6):345-347.
58. Murray C.J., Vos T., Lozano R., et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380(9859):2197-2223.
59. Garnett G.P. The theoretical impact of vaccines that protect against sexually transmitted infections and disease. Vaccine 2013, current issue.
60. Owusu-Edusei K., Chesson H.W., Gift T.L., et al. The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008. Sex Transm Dis 2013, 40(3):197-201.
61. World Health Organization Global strategy for the prevention and control of sexually transmitted infections: 2006-2015: breaking the chain of transmission. 2007, World Health Organization, Geneva, http://www.who.int/reproductivehealth/publications/rtis/9789241563475/en/index.html.
62. Lewis D.A. HIV/sexually transmitted infection epidemiology, management and control in the IUSTI Africa region: focus on sub-Saharan Africa. Sex Transm Infect 2011, 87(Suppl. 2):ii10-ii20.
63. Scholes D., Stergachis A., Heidrich F.E., Andrilla H., Holmes K.K., Stamm W.E. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Engl J Med 1996, 334(21):1362-1366.
64. World Health Organization The global elimination of congenital syphilis: rationale and strategy for action 2007, World Health Organization, Geneva, http://www.who.int/reproductivehealth/publications/rtis/9789241595858/en.
65. Centers for Disease Control and Prevention Sexually transmitted diseases treatment guidelines 2010, MMWR 2010; 59(RR-12).
66. Low N., Broutet N., Adu-Sarkodie Y., Barton P., Hossain M., Hawkes S. Global control of sexually transmitted infections. Lancet 2006, 368(9551):2001-2016.
67. Manhart L.E., Holmes K.K. Randomized controlled trials of individual-level, population-level, and multilevel interventions for preventing sexually transmitted infections: what has worked. J Infect Dis 2005, 191(Suppl. 1):S7-S24.
68. Wetmore C.M., Manhart L.E., Wasserheit J.N. Randomized controlled trials of interventions to prevent sexually transmitted infections: learning from the past to plan for the future. Epidemiol Rev 2010, 32(1):121-136.
69. Centers for Disease Control and Prevention Sexually transmitted disease surveillance 2011 2012, Department of Health and Human Services, Atlanta, U.S., http://www.cdc.gov/std/stats11/Surv2011.pdf.
70. European Centre for Disease Prevention and Control Sexually transmitted infections in Europe 1990-2010. Stockholm: ECDC 2012, http://www.ecdc.europa.eu/en/publications/publications/201206-sexually-transmitted-infections-europe-2010.pdf.
71. Park L.S., Siraprapasiri T., Peerapatanapokin W., Manne J., Niccolai L., Kunanusont C. HIV transmission rates in Thailand: evidence of HIV prevention and transmission decline. J Acquir Immune Defic Syndr 2010, 54(4):430-436.
72. Aral S.O. Utility and delivery of behavioural interventions to prevent sexually transmitted infections. Sex Transm Infect 2011 Dec, 87(Suppl. 2):ii31-ii33.
73. Pettifor A., Walsh J., Wilkins V., Raghunathan P. How effective is syndromic management of STDs? a review of current studies. Sex Transm Dis 2000, 27(7):371-385.
74. Bosch F.X., Burchell A.N., Schiffman M., et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008, 26(Suppl. 10):K1-K16.
75. Geisler W.M. Duration of untreated, uncomplicated Chlamydia trachomatis genital infection and factors associated with chlamydia resolution: a review of human studies. J Infect Dis 2010, 201(Suppl. 2):S104-S113.
76. Tronstein E., Johnston C., Huang M.L., et al. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. JAMA 2011, 305(14):1441-1449.
77. Allen V.G., Mitterni L., Seah C., et al. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA 2013, 309(2):163-170.
78. Kirkcaldy R.D., Bolan G.A., Wasserheit J.N. Cephalosporin-resistant gonorrhea in North America. JAMA 2013, 309(2):185-187.
79. Lewis D.A., Lukehart S.A. Antimicrobial resistance in Neisseria gonorrhoeae and Treponema pallidum: evolution, therapeutic challenges and the need to strengthen global surveillance. Sex Transm Infect 2011, 87(Suppl. 2):ii39-ii43.
80. Bachmann L.H., Hobbs M.M., Sena A.C., et al. Trichomonas vaginalis genital infections: progress and challenges. Clin Infect Dis 2011, 53(Suppl. 3):S160-S172.
81. Kirkcaldy R.D., Augostini P., Asbel L.E., et al. Trichomonas vaginalis antimicrobial drug resistance in 6 US cities, STD Surveillance Network, 2009-2010. Emerg Infect Dis 2012, 18(6):939-943.
82. Manhart L.E., Gillespie C.W., Lowens M.S., et al. Standard treatment regimens for nongonococcal urethritis have similar but declining cure rates: a randomized controlled trial. Clin Infect Dis 2013, 56(7):934-942.
83. Batteiger B.E., Xu F., Johnson R.E., Rekart M.L. Protective immunity to Chlamydia trachomatis genital infection: evidence from human studies. J Infect Dis 2010, 201(Suppl. 2):S178-S189.
84. Geisler W.M., Lensing S.Y., Press C.G., Hook E.W. Spontaneous resolution of genital Chlamydia trachomatis infection in women and protection from reinfection. J Infect Dis 2013, 207(12):1850-1856.
85. Das A., Pathni A.K., Narayanan P., et al. High rates of reinfection and incidence of bacterial sexually transmitted infections in a cohort of female sex workers from two Indian cities: need for different STI control strategies?. Sex Transm Infect 2013, 89(1):5-10.
86. Hosenfeld C.B., Workowski K.A., Berman S., et al. Repeat infection with chlamydia and gonorrhea among females: a systematic review of the literature. Sex Transm Dis 2009, 36(8):478-489.
87. Peeling R.W. Applying new technologies for diagnosing sexually transmitted infections in resource-poor settings. Sex Transm Infect 2011, 87(Suppl. 2):ii28-ii30.
88. Datta S.D., Torrone E., Kruszon-Moran D., et al. Chlamydia trachomatis trends in the United States among persons 14 to 39 years of age, 1999-2008. Sex Transm Dis 2012, 39(2):92-96.
89. Heijne J.C., Tao G., Kent C.K., Low N. Uptake of regular chlamydia testing by U.S. women: a longitudinal study. Am J Prev Med 2010, 39(3):243-250.
90. Freeman E.E., Orroth K.K., White R.G., et al. Proportion of new HIV infections attributable to herpes simplex 2 increases over time: simulations of the changing role of sexually transmitted infections in sub-Saharan African HIV epidemics. Sex Transm Infect 2007, 83(Suppl. 1):i17-i24.
91. Celum C., Wald A., Hughes J., et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008, 371(9630):2109-2119.
92. Corey L., Ashley R. Prevention of herpes simplex virus type 2 transmission with antiviral therapy. Herpes 2004, 11(Suppl. 3):170A-174A.
93. Tobian A.A., Serwadda D., Quinn T.C., et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med 2009, 360(13):1298-1309.
94. Tan D. Potential role of tenofovir vaginal gel for reduction of risk of herpes simplex virus in females. Int J Womens Health 2012, 4:341-350.
95. Marrazzo J., Ramjee G., Nair G. VOICE Study Team. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE Study (MTN 003) 2013, http://www.retroconference.org/2013b/Abstracts/47951.htm.
96. Freeman E.E., White R.G., Bakker R., et al. Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa. Vaccine 2009, 27(6):940-946.
97. Johnston C., Koelle D.M., Wald A. Current status and prospects for development of an HSV-2 vaccine. Vaccine 2013, current issue.
98. Low N., Cassell J.A., Spencer B., et al. Chlamydia control activities in Europe: cross-sectional survey. Eur J Public Health 2012, 22(4):556-561.
99. Gottlieb S.L., Xu F., Brunham R.C. Screening and treating Chlamydia trachomatis genital infection to prevent pelvic inflammatory disease: interpretation of findings from randomized controlled trials. Sex Transm Dis 2013, 40(2):97-102.
100. Brunham R.C., Rekart M.L. The arrested immunity hypothesis and the epidemiology of chlamydia control. Sex Transm Dis 2008, 35(1):53-54.
101. Gottlieb S.L., Martin D.H., Xu F., Byrne G.I., Brunham R.C. Summary: The natural history and immunobiology of Chlamydia trachomatis genital infection and implications for chlamydia control. J Infect Dis 2010, 201(Suppl. 2):S190-S204.
102. Hafner L.M., Wilson D.P., Timms P. Development status and future vaccines for Chlamydia trachomatis infections. Vaccine 2013, current issue.
103. Jerse A.E., Bash M.C., Russell M.W. Vaccines against gonorrhea: current status and future challenges. Vaccine 2013, current issue.
104. Smith J., Garber G.E. Current status and prospects for development of a vaccine against Trichomonas infections. Vaccine 2013, current issue.
105. Hawkes S., Matin N., Broutet N., Low N. Effectiveness of interventions to improve screening for syphilis in pregnancy: a systematic review and meta-analysis. Lancet Infect Dis 2011, 11(9):684-691.
106. Cameron C.E., Lukehart S.A. Current status of syphilis vaccine development: need, challenges, prospects. Vaccine 2013, current issue.
107. Goldie S.J., O'Shea M., Diaz M., Kim S.Y. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications. Reprod Health Matters 2008, 16(32):86-96.
108. Broutet N., Lehnert N., Mehl Geal Effective health interventions for adolescents that could be integrated with human papillomavirus vaccination programs. J Adolesc Health 2013, doi:pii: S1054-139X(13)00144-4.